PaxMedica to discuss significance of Phase 3 study results Interview to be webcast on Tuesday, August 15, 2023, at 10:30 am ET TARRYTOWN, NY, August 8, 2023 - PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, will join PCG Advisory for a Fireside Chat on Tuesday, August 15, 2023,...